Want to see INM full AI Analyst Report?
INM Stock Chart & Stats
$1.12
-$0.34(-7.10%)
At close: 4:00 PM EST
$1.12
-$0.34(-7.10%)
Day’s Range― - ―
52-Week Range$0.58 - $2.50
Previous CloseN/A
Volume49.03K
Average Volume (3M)113.41K
Market Cap
$4.87M
Enterprise Value-$2.17
Total Cash (Recent Filing)$5.20M
Total Debt (Recent Filing)$420.15K
Price to Earnings (P/E)―
Beta3.41
Next Earnings
Sep 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1142.54
Shares Outstanding3,314,063
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthVery low reported leverage reduces refinancing and solvency risk, giving management flexibility to pursue R&D and strategic options over the medium term. A conservative capital structure supports survival through development cycles even while profitability is absent.
Substantial Merger Financing Extends RunwayLarge pre-merger private placements tied to the Mentari transaction materially lengthen the combined company’s funded runway and finance Phase 2a programs. Secured growth capital reduces near-term dilution pressure and materially lowers immediate funding risk for development milestones.
Nasdaq Listing Compliance RestoredRestored listing compliance removes a structural market-access risk, improving the company’s ability to raise capital, maintain index/accessibility and execute corporate actions. This durable operational stability supports longer-term financing and strategic planning.
Bears Say
Persistent Cash Burn / Negative Free Cash FlowSustained negative operating and free cash flow means the company must rely on external financing or dilution to fund operations. That structural cash burn elevates execution and funding risk across the next several quarters, constraining the ability to self-fund pipeline development.
Weak Profitability And Low Gross MarginsLow gross margins and continued operating losses suggest the current revenue mix cannot support scalable profitability. Without margin expansion or cost structure changes, long-term value creation is unlikely and reliance on external capital will remain high.
Severe Dilution / Governance Shift From MergerThe all-stock reverse merger results in a near-total ownership transfer and governance control to Mentari stakeholders, materially diluting legacy holders and ceding board/management control. That structural change limits upside for incumbents and creates execution risk tied to new owners' priorities.
InMed Pharmaceuticals News
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.57 and its highest was $2.50 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $4.87M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Sep 18, 2026 which is in 46 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$0.733 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 3,314,063 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$0.733 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.132%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Ownership Overview
60.53% Insiders
0.15% Other Institutional Investors
39.32% Public Companies and
Individual Investors